Literature DB >> 32873405

Cost estimates of diarrhea hospitalizations among children <5 years old in Zimbabwe.

Hilda A Mujuru1, Eleanor Burnett2, Kusum J Nathoo3, Ismail Ticklay4, Nhamo A Gonah5, Arnold Mukaratirwa6, Chipo Berejena6, Portia Manangazira7, Maxwell Rupfutse8, Tyler Chavers2, Goitom G Weldegebriel9, Jason M Mwenda10, Umesh D Parashar2, Jacqueline E Tate2.   

Abstract

INTRODUCTION: Diarrhoea is a leading killer of children <5 years old, accounting for 480,000 deaths in 2017. Zimbabwe introduced Rotarix into its vaccination program in 2014. In this evaluation, we estimate direct medical, direct non-medical, and indirect costs attributable to a diarrhea hospitalization in Zimbabwe after rotavirus vaccine introduction.
METHODS: Children <5 years old admitted to Harare Central Hospital from June 2018 to April 2019 with acute watery diarrhea were eligible for this evaluation. A 3-part structured questionnaire was used to collect data by interview from the child's family and by review of the medical record. A stool specimen was also collected and tested for rotavirus. Direct medical costs were the sum of medications, consumables, diagnostic tests, and service delivery costs. Direct non-medical costs were the sum of transportation, meals and lodging for caregivers. Indirect costs are the lost income for household members.
RESULTS: A total of 202 children were enrolled with a median age of 12 months (IQR: 7-21) and 48 (24%) had malnutrition. Children were sick for a median of 2 days and most had received outpatient medical care prior to admission. The median monthly household income was higher for well-nourished children compared to malnourished children (p < 0.001). The median total cost of a diarrhea illness resulting in hospitalization was $293.74 (IQR: 188.42, 427.89). Direct medical costs, with a median of $251.74 (IQR: 155.42, 390.96), comprised the majority of the total cost. Among children who tested positive for rotavirus, the median total illness cost was $243.78 (IQR: 160.92, 323.84). The median direct medical costs were higher for malnourished than well-nourished children (p < 0.001).
CONCLUSION: Direct medical costs are the primary determinant of diarrhea illness costs in Zimbabwe. The descriptive findings from this evaluation are an important first step in calculating the cost effectiveness of rotavirus vaccine. Published by Elsevier Ltd.

Entities:  

Keywords:  Cost; Diarrhea; Economic burden; Rotavirus; Zimbabwe

Mesh:

Substances:

Year:  2020        PMID: 32873405      PMCID: PMC8082468          DOI: 10.1016/j.vaccine.2020.08.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.

Authors:  Deborah E Atherly; Kristen D C Lewis; Jacqueline Tate; Umesh D Parashar; Richard D Rheingans
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

2.  A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia.

Authors:  Laura K Beres; Jacqueline E Tate; Lungowe Njobvu; Bertha Chibwe; Cheryl Rudd; M Brad Guffey; Jeffrey S A Stringer; Umesh D Parashar; Roma Chilengi
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079

3.  Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.

Authors:  Charles Sigei; John Odaga; Mercy Mvundura; Yvette Madrid; Andrew David Clark
Journal:  Vaccine       Date:  2015-05-07       Impact factor: 3.641

Review 4.  Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016.

Authors:  Christine L Jonesteller; Eleanor Burnett; Catherine Yen; Jacqueline E Tate; Umesh D Parashar
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

5.  Rotavirus vaccines. WHO position paper – January 2013.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2013-02-01

6.  The economic burden of diarrheal disease in a tertiary level hospital, Gauteng, South Africa.

Authors:  Una E MacIntyre; Francois P R de Villiers
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

7.  116E rotavirus vaccine development: a successful alliance.

Authors:  Shabir A Madhi; Umesh D Parashar
Journal:  Lancet       Date:  2014-03-12       Impact factor: 79.321

8.  Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.

Authors:  Frédéric Debellut; Andrew Clark; Clint Pecenka; Jacqueline Tate; Ranju Baral; Colin Sanderson; Umesh Parashar; Laura Kallen; Deborah Atherly
Journal:  Lancet Glob Health       Date:  2019-12       Impact factor: 26.763

9.  Monovalent Rotavirus Vaccine Effectiveness Against Rotavirus Hospitalizations Among Children in Zimbabwe.

Authors:  Hilda A Mujuru; Eleanor Burnett; Kusum J Nathoo; Ismail Ticklay; Nhamo A Gonah; Arnold Mukaratirwa; Chipo Berejena; Portia Manangazira; Maxwell Rupfutse; Goitom G Weldegebriel; Jason M Mwenda; Catherine Yen; Umesh D Parashar; Jacqueline E Tate
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

10.  The Economic Burden Attributable to a Child's Inpatient Admission for Diarrheal Disease in Rwanda.

Authors:  Fidele Ngabo; Mercy Mvundura; Lauren Gazley; Maurice Gatera; Celse Rugambwa; Eugene Kayonga; Yvette Tuyishime; Jeanne Niyibaho; Jason M Mwenda; Philippe Donnen; Philippe Lepage; Agnes Binagwaho; Deborah Atherly
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.